Back to top
more

Novo Nordisk (NVO)

(Delayed Data from NYSE)

$48.19 USD

48.19
34,745,445

+1.12 (2.38%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $48.34 +0.15 (0.31%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (96 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

AbbVie Inc's. (ABBV) Q2 Earnings: Disappointment in Store?

by Zacks Equity Research

AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company toward an earnings beat in Q2 despite a negative Earnings ESP posing a threat to the stock.

    Zacks Equity Research

    Can Merck (MRK) Pull Off a Surprise this Earnings Season?

    by Zacks Equity Research

    Merck & Co., Inc.'s (MRK) new products like Keytruda, Zepatier and Bridion are likely to drive sales in Q2. However, headwinds remain in the form genericization of key drugs and increasing competition.

      Zacks Equity Research

      Is Novo Nordisk (NVO) Stock a Solid Choice Right Now?

      by Zacks Equity Research

      Novo Nordisk (NVO) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.

        Zacks Equity Research

        What Lies in Store for Glaxo (GSK) this Earnings Season?

        by Zacks Equity Research

        The performance of GlaxoSmithKline plc's (GSK) new products is likely to be good. Vaccines acquired from Novartis are likely to drive revenues and ease the impact of the loss of key drug, Advair.

          Ryan McQueeney headshot

          Why Did Radius Health (RDUS) Stock Plummet Today?

          by Ryan McQueeney

          Shares of Radius Health (RDUS) dropped more than 7.8% in early morning trading hours Monday after the company announced that Jesper Hoiland, a former top-ranking executive at Novo Nordisk (NVO), has been appointed its new president and chief executive officer.

            Arpita Dutt headshot

            Pharma Stock Roundup: NVS Scores with Positive Data, Shire ADHD Drug Gets FDA Nod

            by Arpita Dutt

            All major pharma stocks were up this week with companies like Novartis (NVS) presenting positive data and others gaining FDA approval.

              Zacks Equity Research

              Why You Should Add Novo Nordisk Stock to Your Portfolio

              by Zacks Equity Research

              Novo Nordisk (NVO) is healthcare company and a with leadership in the global diabetes market. It looks like a great stock to buy now.

                Zacks Equity Research

                Novo Nordisk's Victoza Gets FDA Panel Nod for Label Expansion

                by Zacks Equity Research

                Novo Nordisk A/S (NVO) announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the FDA voted 17-2 in favor of Victoza that the drug provides substantial evidence of cardiovascular risk reduction in patients with type II diabetes.

                  Zacks Equity Research

                  Novo Nordisk (NVO) Presents Data for Type II Diabetes Drug

                  by Zacks Equity Research

                  Novo Nordisk (NVO) announced positive results from the post-hoc analysis of the cardiovascular outcomes study, LEADER on Victoza.

                    Zacks Equity Research

                    Merck's Diabetes Drug Meets Primary Endpoint in Key Studies

                    by Zacks Equity Research

                    Merck & Co., Inc. (MRK) and partner Pfizer Inc. (PFE) announced that its pipeline candidate, ertugliflozin, met primary endpoints in two late stage studies evaluating ertugliflozin in adults with Type 2 diabetes.

                      Arpita Dutt headshot

                      Key FDA Events to Watch Out for in Jun 2017

                      by Arpita Dutt

                      Companies like Portola (PTLA) are awaiting key FDA decisions this month which could send their stocks soaring in case of a positive response.

                        Zacks Equity Research

                        Novo Nordisk's (NVO) Drug Gets FDA Approval for Hemophilia B

                        by Zacks Equity Research

                        Novo Nordisk (NVO) announced that the FDA has approved the Biologics License Application (BLA) for Rebinyn (Coagulation Factor IX (Recombinant), GlycoPEGylated) for the treatment of adults and children with hemophilia B.

                          Zacks Equity Research

                          5 Reasons Why VIVUS (VVUS) Stock Should Be in Your Portfolio

                          by Zacks Equity Research

                          Campbell, CA -based VIVUS, Inc. (VVUS) is a biopharmaceutical company developing and commercializing innovative, next-generation therapies to address unmet medical needs

                            Zacks Equity Research

                            AstraZeneca's Bydureon Fails to Reduce Cardiovascular Risk

                            by Zacks Equity Research

                            AstraZeneca plc (AZN) announced top-line results from the EXSCEL study evaluating the cardiovascular (CV) safety profile of its type II diabetes drug Bydureon.

                              Zacks Equity Research

                              Novo Nordisk (NVO) Beats on Q1 Earnings, Revenues Down Y/Y

                              by Zacks Equity Research

                              Novo Nordisk A/S (NVO) reported first-quarter 2017 earnings of 58 cents per American Depositary Receipt (ADR) beating the Zacks Consensus Estimate of 53 cents by 9.4%.

                                Arpita Dutt headshot

                                6 FDA Events to Watch Out for in May 2017

                                by Arpita Dutt

                                Here is a look at a few important regulatory events scheduled for the month of May including the FDA's decision regarding the label expansion of Merck's (MRK) Keytruda.

                                  Zacks Equity Research

                                  Merck's Bid to Add Cardiovascular Data on Januvia Label Fails

                                  by Zacks Equity Research

                                  Merck announced that the FDA has denied approval to include cardiovascular outcomes data on the labels of its diabetes drug, Januvia (sitagliptin) and other medicines containing Januvia.

                                    Zacks Equity Research

                                    Novo Nordisk: Positive CHMP Nod for Tresiba Label Expansion

                                    by Zacks Equity Research

                                    Novo Nordisk A/S (NVO) announced that the Committee for Medicinal Products for Human Use (CHMP), has issued a positive opinion suggesting an update to the label for Tresiba (insulin degludec) to include data from the SWITCH studies.

                                      Zacks Equity Research

                                      Orexigen Inks Commercialization Deal for Contrave, Stock Up

                                      by Zacks Equity Research

                                      Orexigen Therapeutics, Inc.'s (OREX) announced that it has entered into a commercialization and distributorship agreement with Italian pharmaceutical company, Bruno Farmaceutici, for its obesity drug, Contrave.

                                        Zacks Equity Research

                                        Novo Nordisk's Diabetes Unit Strong; Generic Pressure Stays

                                        by Zacks Equity Research

                                        We issued an updated research report on Novo Nordisk (NVO) on Mar 9, 2017.

                                          Zacks Equity Research

                                          Merck/Pfizer's Diabetes Drug Accepted for Review by FDA, EMA

                                          by Zacks Equity Research

                                          Merck & Co., Inc. (MRK) and partner Pfizer, Inc. (PFE) announced that the FDA has accepted its new drug applications (NDA) for ertugliflozin as a monotherapy as well as two fixed-dose combination tablets.

                                            Zacks Equity Research

                                            Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International

                                            by Zacks Equity Research

                                            Zacks Industry Outlook Highlights: Sanofi, AstraZeneca, Novo Nordisk, Gilead Sciences and Valeant Pharmaceuticals International

                                              Sheraz Mian headshot

                                              Top Analyst Reports for Priceline, Schwab & NextEera Energy

                                              by Sheraz Mian

                                              Today's Research Daily features new research reports on 16 major stocks, including Priceline (PCLN), NextEra Energy (NEE) and Schwab (SCHW).

                                                Zacks Equity Research

                                                Novo Nordisk Inks Diabetes Deal with University of Oxford

                                                by Zacks Equity Research

                                                Novo Nordisk A/S (NVO) and University of Oxford announced a landmark research collaboration for the treatment of type II diabetes.

                                                  Zacks Equity Research

                                                  Novo Nordisk (NVO) Fiasp Gets EU Nod for Diabetes in Adults

                                                  by Zacks Equity Research

                                                  Novo Nordisk (NVO) announced that its fast-acting insulin aspart, Fiasp, has been approved in the EU for the treatment of diabetes in adults.